Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Catalio Capital Management LP

Catalio Capital Management LP lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 44.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 162,550 shares of the biopharmaceutical company’s stock after selling 128,712 shares during the quarter. Catalio Capital Management LP’s holdings in Ultragenyx Pharmaceutical were worth $3,739,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. 683 Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 109.8% during the 4th quarter. 683 Capital Management LLC now owns 222,395 shares of the biopharmaceutical company’s stock worth $5,115,000 after acquiring an additional 116,395 shares during the period. Guggenheim Capital LLC boosted its position in Ultragenyx Pharmaceutical by 4.4% during the 4th quarter. Guggenheim Capital LLC now owns 49,137 shares of the biopharmaceutical company’s stock worth $1,130,000 after acquiring an additional 2,061 shares during the period. PDT Partners LLC boosted its position in Ultragenyx Pharmaceutical by 12.8% during the 4th quarter. PDT Partners LLC now owns 176,813 shares of the biopharmaceutical company’s stock worth $4,067,000 after acquiring an additional 20,120 shares during the period. AQR Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 82.3% during the 4th quarter. AQR Capital Management LLC now owns 1,360,497 shares of the biopharmaceutical company’s stock worth $31,291,000 after acquiring an additional 614,315 shares during the period. Finally, Trexquant Investment LP boosted its position in Ultragenyx Pharmaceutical by 6.2% during the 4th quarter. Trexquant Investment LP now owns 165,017 shares of the biopharmaceutical company’s stock worth $3,795,000 after acquiring an additional 9,629 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director directly owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 24,002 shares of company stock valued at $575,039. 5.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Barclays cut their price objective on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Cantor Fitzgerald upped their price objective on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, May 21st. Wedbush cut their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Canaccord Genuity Group cut their price objective on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $59.56.

Ultragenyx Pharmaceutical Stock Up 8.3%

Shares of NASDAQ RARE opened at $26.91 on Thursday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -4.40 and a beta of 0.37. The business has a fifty day simple moving average of $24.17 and a 200-day simple moving average of $24.91.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million for the quarter, compared to analysts’ expectations of $158.19 million. During the same period in the prior year, the company earned ($1.57) earnings per share. The company’s revenue for the quarter was down 2.2% on a year-over-year basis. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.